Targeting Soluble Epoxide Hydrolase and Cyclooxygenases Enhance Joint Pain Control, Stimulate Collagen Synthesis, and Protect Chondrocytes From Cytokine-Induced Apoptosis.
Authors: Tucker Laura, Trumble Troy N, Groschen Donna, Dobbs Erica, Baldo Caroline F, Wendt-Hornickle Erin, Guedes Alonso G P
Journal: Frontiers in veterinary science
Summary
# Editorial Summary In an experimentally induced joint inflammation model, Tucker and colleagues investigated whether combining conventional non-steroidal anti-inflammatory drugs (NSAIDs) with soluble epoxide hydrolase (sEH) inhibitors could provide superior therapeutic benefits compared to either approach alone. Using a blinded crossover design in six healthy horses, they induced radiocarpal joint inflammation with lipopolysaccharide whilst administering phenylbutazone, the sEH inhibitor t-TUCB, or both agents in various doses, then tracked pain responses (via inertial movement sensors), synovial fluid inflammatory markers, and cartilage turnover biomarkers over 48 hours alongside in vitro chondrocyte apoptosis assays. The dual-therapy approach significantly outperformed monotherapy in controlling lameness and maintaining a favourable balance between collagen synthesis and degradation; whilst COX inhibition alone was superior for pain control, sEH inhibition uniquely protected cartilage cells from inflammatory cytokine-induced death—a protective effect that was potentiated when combined with NSAIDs. These findings suggest that combining traditional NSAIDs with sEH inhibitors offers genuine disease-modifying potential beyond symptomatic relief, though the practical application of sEH inhibitors in equine practice remains to be determined as they are not yet routinely available in clinical settings.
Read the full abstract on PubMed
Practical Takeaways
- •Combining sEH and COX inhibitors may offer superior pain relief and cartilage protection in joint disease compared to NSAIDs alone—consider investigating dual-therapy protocols for horses with osteoarthritis
- •sEH inhibitors appear to have disease-modifying potential by protecting cartilage cells from inflammatory damage, not just symptom relief
- •This work supports exploring sEH inhibitors as adjunctive therapy alongside traditional NSAIDs for conditions like radiocarpal joint disease
Key Findings
- •Combined COX and sEH inhibition provided superior joint pain control compared to either drug alone in LPS-induced joint inflammation
- •sEH inhibition combined with phenylbutazone improved collagen synthesis-degradation balance, whereas COX inhibition alone did not
- •sEH inhibition alone or with COX inhibitors protected chondrocytes from TNF-α-induced apoptosis, but COX inhibition alone was ineffective
- •sEH-generated metabolites caused concentration-dependent chondrocyte apoptosis, suggesting sEH inhibition protects cartilage health